Search

Your search keyword '"Fu CL"' showing total 2 results
Start Over Author "Fu CL" Journal american journal of hematology
2 results on '"Fu CL"'

1. Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation.

Author

Saba L, Fu CL, Khouri J, Faiman B, Anwer F, and Chaulagain CP

Subjects
Humans, Male, Female, Multiple Myeloma therapy, Multiple Myeloma diagnosis, Patient Education as Topic
Abstract

The findings of this study highlight a 95% accuracy rate in ChatGPT responses, as assessed by five myeloma specialists, underscoring its potential as a reliable educational tool., (© 2024 Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

2. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.

Author

Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, Khursigara G, Fu CL, Omine M, Browne P, and Rosse W

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Complement Activation drug effects, Complement C5 immunology, Female, Glomerular Filtration Rate drug effects, Hemoglobinuria, Paroxysmal complications, Hemoglobinuria, Paroxysmal immunology, Hemoglobinuria, Paroxysmal physiopathology, Hemolysis drug effects, Humans, Kidney drug effects, Kidney Failure, Chronic drug therapy, Kidney Failure, Chronic etiology, Kidney Failure, Chronic physiopathology, Male, Metabolic Clearance Rate drug effects, Middle Aged, Pilot Projects, Severity of Illness Index, Treatment Outcome, Young Adult, Antibodies, Monoclonal therapeutic use, Complement C5 antagonists & inhibitors, Complement Inactivating Agents therapeutic use, Hemoglobinuria, Paroxysmal drug therapy, Kidney physiopathology, Kidney Failure, Chronic prevention & control
Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a debilitating and life-threatening disease in which lysis of PNH red blood cells frequently manifests with chronic hemolysis, anemia, and thrombosis. Renal damage in PNH is associated with chronic hemosiderosis and/or microvascular thrombosis. We determined the incidence of renal dysfunction or damage, defined by stages of chronic kidney disease (CKD), in a large cohort of PNH patients and evaluated the safety and efficacy of the complement inhibitor eculizumab in altering its progression. Renal dysfunction or damage was observed in 65% of the study population at baseline with 21% of patients with later stage CKD or kidney failure (glomerular filtration rate [GFR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results